Table 2 Description of the therapeutic management of the BD patients enrolled in the study (N = 344)
N | % | |
|---|---|---|
Li | 67 | 19.4 |
Li + qutiapine | 17 | 4.9 |
Li + olanzapine | 10 | 2.9 |
Li + lurasidone | 5 | 1.4 |
Li + dvp + quetiapine | 55 | 15.9 |
Li + dvp + olanzapine | 27 | 7.8 |
Li + lamotrigine + quetiapine | 26 | 7.5 |
Li + lamotrigine + olanzapine | 24 | 6.9 |
Li + dvp + aripiprazole | 9 | 2.6 |
dvp + qutiapine | 47 | 13.6 |
dvp + olanzpine | 22 | 6.3 |
dvp + lurasidone | 4 | 1.1 |
dvp + aripiprazole | 9 | 2.6 |
lamotrigine + olanzapine | 9 | 2.6 |
lamotrigine + quetiapine | 7 | 2.03 |
carbamazepine + quetiapine | 6 | 1.7 |